1. Home
  2. ECPG vs MIRM Comparison

ECPG vs MIRM Comparison

Compare ECPG & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Encore Capital Group Inc

ECPG

Encore Capital Group Inc

HOLD

Current Price

$53.97

Market Cap

905.2M

Sector

Finance

ML Signal

HOLD

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$65.07

Market Cap

3.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ECPG
MIRM
Founded
1998
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
905.2M
3.7B
IPO Year
1999
2019

Fundamental Metrics

Financial Performance
Metric
ECPG
MIRM
Price
$53.97
$65.07
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
11
Target Price
$61.67
$87.55
AVG Volume (30 Days)
248.7K
545.4K
Earning Date
11-05-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,560,869,000.00
$471,794,000.00
Revenue This Year
$31.88
$53.78
Revenue Next Year
$3.57
$19.91
P/E Ratio
N/A
N/A
Revenue Growth
17.52
53.66
52 Week Low
$26.45
$36.88
52 Week High
$56.67
$78.55

Technical Indicators

Market Signals
Indicator
ECPG
MIRM
Relative Strength Index (RSI) 61.15 36.47
Support Level $52.51 $63.66
Resistance Level $56.67 $66.77
Average True Range (ATR) 1.79 2.99
MACD 0.08 -0.66
Stochastic Oscillator 59.36 13.68

Price Performance

Historical Comparison
ECPG
MIRM

About ECPG Encore Capital Group Inc

Encore Capital Group Inc is an international specialty finance company. It provides debt recovery solutions for consumers and property owners across a broad range of financial assets. The company purchases portfolios of defaulted consumer receivables at deep discounts to face value and manages them by working with individuals as the consumers repay their obligations and work toward financial recovery. Encore has only a reportable segment portfolio purchasing and recovery.

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Share on Social Networks: